Notícias e Atividades da Shin Nippon Biomedical Laboratories

Shin Nippon Biomedical Laboratories é uma das ...

• TOB Iconic 10,000;
• Topix.

Shin Nippon Biomedical Laboratories é uma empresa listada sob o símbolo 2395 (JP).

Veja o organograma con seus 27 executivos principais

Biografias mais buscadas da Shin Nippon Biomedical Laboratories

• Ryoichi Nagata, Chairman of the Board, Chief Executive Officer, Ch...
• Takashi Yamashita, Non-Executive Independent Director
• Shinichi Fukumoto, Non-Executive Independent Director

Criar um alerta
para seguir os movimentos de executivos da Shin Nippon Biomedical Laboratories.

Shin Nippon Biomedical Laboratories possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Shin Nippon Biomedical Laboratories

• Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Wave Life Sciences
• Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency - Wave Life Sciences
• Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease - Wave Life Sciences
• Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping - Wave Life Sciences
• Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares - Wave Life Sciences
• We released materials for presentation on nasal administration basic technology briefing session - SNBL
• Financial News Archive-SNBL
• View more press releases Close

Redes sociais sobre Shin Nippon Biomedical Laboratories

• Shin Nippon Biomedical Laboratories na Wikipedia, Google News e Yahoo Finance
• Shin Nippon Biomedical Laboratories na LinkedIn, Twitter e YouTube